Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
Hospira, Inc. HSP presented data from two studies on a proposed biosimilar, Retacrit (Epoetin Hospira), at the National Kidney Foundation spring meeting. The drug is a proposed biosimilar to Amgen Inc ...
The FDA has approved Pfizer’s biosimilar drug, Retacrit, a cut price competitor Amgen and Johnson & Johnson's bone marrow stimulating drug epoetin alfa. Retacrit (epoetin alfa-epbx), is a biosimilar ...
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today results from a post-marketing study of the company's European biosimilar epoetin, ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results